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From Cancer Stem Cells to Tumor Maintenance in
Melanoma
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The utility of different models to identify cancer stem cells continues to be a subject of intense debate. Here, we
summarize recent efforts to characterize intra-tumoral heterogeneity of melanoma and delineate key questions
for future studies. Within a developing or already established tumor microenvironment, we propose that
continuous tumor maintenance is assured by specific sub-populations whose phenotype is not static but
instead is dynamically regulated. These small and temporarily distinct sub-populations likely have critical roles
in tumor progression. They are important therapeutic targets, but only in the context of combination therapies,
that also eliminate the bulk of the tumor.
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THE EVOLVING DEFINITION OF
CANCER STEM CELLS
In the mid-1990s, Lapidot et al. (1994)
reported that only a small sub-popula-
tion of acute myeloid leukemia (AML)
cells could establish tumors when
transplanted into severe combined im-
munodeficiency (SCID) mice, whereas
the major population could not. The
tumorigenic sub-population was
named ‘‘AML-initiating cells’’, and it
was defined by the presence of the cell
surface marker CD34 and the absence
of CD38. Both markers also represent
immature cells in normal human bone
marrow, which raised the question of
whether CD34þ CD38 cells were
leukemic stem cells. Using non-obese
diabetic (NOD)/SCID mice, which are
more immunocompromised than SCID
mice, it was shown that the CD34þ
CD38 AML sub-population generated
differentiated leukemic progenitors,
which have limited proliferative capa-
city, suggesting that AML leukemic
clones are hierarchically organized
(Bonnet and Dick, 1997). Although
those findings were challenged by
recent reports that AML-initiating cells
are not restricted to the CD34þ CD38
sub-population (Sarry et al., 2010;
Taussig et al., 2010), subsequent stu-
dies in a variety of human solid tumors
confirmed that only subsets of cells
isolated from tumors are able to initiate
growth in SCID or NOD/SCID mice.
‘‘Tumor-initiating’’ sub-populations are
generally characterized by cell surface
markers, which are often shared with
the stem cell populations in the normal
tissue counterparts. In 2006, the field
came to a consensus definition: a
cancer stem cell (CSC) is capable of
self-renewal, can give rise to all hetero-
geneous lineages of the parental tumor,
and has the ability to establish and
maintain continuous tumor growth
(Clarke et al., 2006). In the CSC model,
the direction of differentiation from
stem cells to progenitors and terminally
differentiated cells is hierarchically
organized (Reya et al., 2001). The most
critical aspect of the top-down model
of CSC is that differentiated cells do not
revert back to stem cells unless repro-
gramming events occur (Figure 1a).
THE ‘‘UPS-AND-DOWNS’’ OF THE
CSC MODEL IN MELANOMA
Melanomas are composed of hetero-
geneous cell populations. The diversity
in biological properties and molecular
marker expression has been recognized
for decades and gave rise to specula-
tions on the existence of CSC sub-
populations in melanoma. Following
the pioneering studies on leukemia,
several laboratories including our own
attempted to confirm the existence of
melanoma stem cells using cell surface
markers (Fang et al., 2005; Frank et al.,
2005; Monzani et al., 2007). The
adenosine triphosphate-binding cas-
sette (ABC) transporters compose a
family of trans-membrane proteins that
act as efflux pumps of a variety of
substrates. A wide variety of normal
stem cells including embryonic stem
cells and hematopoietic stem cells
generally express high levels of ABC
transporters such as ABCB1 and
ABCG2 for protection from potentially
damaging influxes (Chaudhary and
Roninson, 1991; Zhou et al., 2001). In
2005, Frank et al. (2005) reported that
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the ABC transporter ABCB5 in melano-
ma mediates doxorubicin resistance.
Three years later, that group reported
that ABCB5-positive melanoma cells
from clinical samples also have in-
creased tumor-initiating capacity when
xenotransplanted into immunodeficient
NOD/SCID mice (Schatton et al.,
2008). In the ABCB5-positive popula-
tion, tumor initiation was achieved
with 105 cells, whereas in the ABCB5-
negative population, 100-fold more
tumor cells were required to form
tumors suggesting that the CSC model
also applied to melanoma. Also in
2008, Morrison’s group demonstrated
that the frequency of melanoma-initiat-
ing cells is dramatically higher, as high
as one in four tumor cells, regardless of
whether or not the tumors were sepa-
rated into different sub-populations
(Quintana et al., 2008). The sum of
the data indicates that the potential for
tumor initiation is not restricted to a
rare sub-population but is a common
feature of all or nearly all melanoma
cells. This suggests that melanoma is
not hierarchically organized and
rather follows a dynamic model, in
which sub-populations change de-
pending on microenvironmental sig-
nals (Figure 1b). On the other hand,
very recently Weissman and co-work-
ers (Boiko et al., 2010) supported
the CSC model by describing the
CD271-positive sub-population as
essential to the initiation of tumors
in mice. CD271, a.k.a. low-affinity
nerve growth factor receptor (HUGO
term: NGFR) or p75NTR, is a marker
of neural crest stem cells (Stemple
and Anderson, 1992) and is hetero-
geneously expressed by an average of
17% cells in most melanomas. In the
Boiko et al. (2010) study, CD271-
positive melanoma cells formed tumors
in 72% of xenografts, whereas CD271-
negative cells were tumorigenic in only
7% of xenografts. CD271-positive but
not CD271-negative melanoma cells
also formed distant metastases. More
recently, Ghadially’s group (Boonyar
atanakornkit et al., 2010) isolated
melanoma cells with a tumor-initiating
property based on the activity of
aldehyde dehydrogenase (ALDH),
which is a functional marker for hema-
topoietic stem cells. It has been sug-
gested that an ALDH-positive cell
population is correlated with poor
clinical prognosis in solid tumors such
as breast or prostate cancers (Ma and
Allan, 2010). In their study, one in
four of ALDH-positive cells initiated
tumors in NSG (NOD/SCID IL2Rgnull)
mice, while only 1 in 600 ALDH-
negative cells and 1 in 400 unsegre-
gated cells did. Both the CD271 and
the ALDH studies support the concept
of CSC in melanoma, where only a
subset of cells drives progression. How-
ever, the most recent report from the
Morrison laboratory contradicts the
findings of the Frank and Weissman
laboratories (Quintana et al., 2010). In
their refined model system, Morrison
and co-workers report that ABCB5-
positive and ABCB5-negative melano-
ma cells are equally tumorigenic when
injecting as few as 10 cells. No
differences were found in the meta-
static capacities of CD271-positive
versus CD271-negative melanoma
cells. Both marker-positive and -nega-
tive cells reproduced intra-tumoral
heterogeneity similar to the parental
tumors and marker-negative sub-popu-
lations gave rise to marker-positive
cells. These data imply that neither
ABCB5 nor CD271 can be classified
as CSC markers in Morrison’s experi-
mental model.
WHAT CAUSES THE DISCREPANCY?:
THE DEVIL IS IN THE DETAILS
Limiting dilution assays in immuno-
compromised mice are a widely ap-
proved method to demonstrate that a
selected marker enriches for tumor
stemness. Although all groups applied
this technique, there are considerable
differences between each experimental
system. To study the ABCB5-positive
sub-population, Frank’s group used
NOD/SCID mice that have impaired
T and B cell lymphocyte development,
yet still maintain natural killer cell
activity, which interferes with engraft-
ment efficiency. In contrast, Morrison’s
group used the more immunocompro-
mised NSG mouse model (Ito et al.,
2002), which lacks natural killer cell
activity in addition to T and B cell
depletion. Furthermore, the latter
group co-injected tumor cells with
Matrigel (BD Biosciences, San Jose,
CA), which consists of collagen type
IV, laminin and other matrix proteins,
to mimic the extracellular environment
in the tumor tissue, and Matrigel may
act to stimulate angiogenesis and/or
growth (Mortarini et al., 1995). For
the CD271 study, Weissman’s group
a Hierarchical CSC model b Dynamic, TME-driven model
Figure 1. Models of sustained tumor propagation. (a) Hierarchal cancer stem cell model. Self-renewing (indicated by red arrows) CSCs sustain the stem cell
population while giving rise to progenitor cells that are not capable of self-renewal. These progenitor cells can give rise to differentiating clones of varying
dominance that contribute to overall tumor heterogeneity. Differentiated cancer cells do not revert back to CSCs. (b) Tumor microenvironment-driven model.
Cancer cells are clonally evolved, yet may contain phenotypically heterogeneous sub-populations. Virtually every single cell can self-renew and propagate tumors.
The self-renewal capability of each cell is determined by distinct signals from the tumor microenvironment (TME, indicated by blue, orange, and purple rectangles).
CSC, cancer stem cell.
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injected CD271-positive/negative sub-
populations in T-, B- and natural
killer-deficient Rag2/gc/ mice with
Matrigel, which have an equivalent
efficiency of tumor engraftment com-
pared with Morrison’s NSG-Matrigel
model. It is noteworthy that they also
tested the tumor initiation capability of
each sub-population in the mouse–
human chimera model, which has
normal human skin grafted onto the
backs of immunodeficient mice. In this
physiologically more relevant model,
2104 CD271-positive melanoma
cells, but not CD271-negative cells,
formed tumors presumably without
Matrigel. In a very recent paper,
Civenni et al. (2011) showed that both
CD271-positive and CD271-negative
cells form tumors in NSG mouse, but
CD271-negative cells failed in initiat-
ing tumors in nude or NOD/SCID mice.
For the ALDH study, the Ghadially
group utilized the NSG–Matrigel
model. However, they used the regular
Matrigel (product 354234, BD Bio-
sciences), while the Morrison group
used high-protein Matrigel (product
354248, BD Biosciences). Each group
also used different methods to isolate
melanoma cells from the tumor mass,
which is likely critical for the yield of
cells. Weissman’s group digested
minced tumors with collagenases (iso-
forms I and II) and thermolysin at 37 1C
for 3 hours with pipetting every 30min-
utes. In contrast, Morrison’s group
placed the minced tissue in collage-
nase IV for only 20minutes at 37 1C
followed by short incubation with low
concentrations of trypsin, which is a
milder digestion process than Weiss-
man’s method (Shackleton, 2010).
Similarly to Weissman’s protocol,
Frank’s group also digested the tumor
pieces in collagenase for 3 hours at
37 1C. Ghadially’s group incubated
minced tumors in collagenase and
hyaluronidase for 2hours at 37 1C.
Civenni et al. (2011) incubated the tissue
from metastatic melanoma lesions in
collagenase III and dispase for 1 hour at
37 1C with simultaneous mincing to
obtain single-cell suspensions. Taking
into account such significant procedural
differences, one may question whether
the ABCB5/CD271/ALDH-positive cells
are simply more capable of surviving
harsh conditions during the digestion
irrespective of any tumor-propagating
ability. However, selective ablation of
ABCB5þ cells by anti-ABCB5 antibo-
dies reduced tumor growth and forma-
tion in xenografts on nude mice from
unsegregated tumors (Schatton et al.,
2008). We observed that the expression
of ABCB5 and the in vivo lung coloniza-
tion in NSG mice are both decreased in
melanoma cells when matricellular pro-
tein tenascin C is disrupted (Fukunaga-
Kalabis et al., 2010), suggesting that
matricellular proteins cooperate with
ABCB5 to stimulate tumor growth and
metastasis. Recently, Frank and
co-workers added another level of com-
plexity by demonstrating that the
ABCB5-positive sub-population sup-
presses T cell activation, suggesting an
immune-evasive capacity of this sub-
population (Schatton et al., 2010).
This observation needs to be validated
in different mouse models such as
‘‘humanized mice’’, which have
reconstituted human immune system
components (Ishikawa et al., 2005;
Strowig et al., 2009) or in mouse genetic
models similar to the CSC studies from
the Bosenberg laboratory (Held et al.,
2010).
DOES TUMOR INITIATION REFLECT
THE TRUE CHARACTER OF TUMOR
STEMNESS?
The field is reaching a consensus that in
principle every one in four melanoma
cells harbors the potential to recapitu-
late tumor growth in a murine environ-
ment if the chosen host is permissive
enough (e.g., NSG mouse). However,
we have to ask whether the concept of
tumor initiation in xenotransplantation
models is a good model for determin-
ing tumor stemness, i.e., the mainte-
nance of continuous tumor growth
(Adams and Strasser, 2008). In most
xenograft models, human melanoma
cells are injected under the skin, where
they are surrounded by fascia. In
patients, the malignant cells are sur-
rounded by stromal, inflammatory, and
immune cells, including fibroblasts,
endothelial cells, macrophages, T cells,
and B cells. Thus, tumor initiation by
the injection of a few tumor cells into
the subcutaneous space measures the
ability of adjusting to a foreign micro-
environment and host-derived growth
factors rather than continuous tumor
maintenance (Adams and Strasser,
2008). In this respect, congenic trans-
plantation of murine lymphoma cells
revealed that tumor initiation is not
necessarily restricted to a minor popu-
lation (Kelly et al., 2007).
Looking for alternative concepts, our
laboratory has been asking whether
tumor stemness could be better re-
flected by an assay measuring the
long-term maintenance of an already
established tumor. In different melano-
ma cell lines, we identified a slow-
cycling sub-population of melanoma
cells representing only 1–5% of all cells
that had stem-like properties (Roesch
et al., 2010). These cells were char-
acterized by high expression of JAR-
ID1B (HUGO term: KDM5B), a
member of the histone 3 lysine 4
demethylase family, which is critical
in regulating gene expression and
cellular identities and is an epigenetic
marker for embryonic stem cells (Chris-
tensen et al., 2007; Iwase et al., 2007;
Klose et al., 2007; Yamane et al.,
2007). When separated from JAR-
ID1B-negative cells, JARID1B-positive,
non-proliferating melanoma cells gave
rise to a rapidly proliferating progeny
that reconstituted the parental hetero-
geneity of JARID1B-positive and -nega-
tive cells. Stable knockdown of
JARID1B led to an initial acceleration
of tumor growth followed by exhaus-
tion, as determined by serial xenotrans-
plantation in NSG mice, suggesting that
JARID1B has an essential role in con-
tinuous melanoma growth. In contrast
to studies in the Frank, Weissman,
Ghadially, and Morrison laboratories,
we used a combination of serial
xenotransplantations plus stable enfor-
cement of a distinct (in this case
‘‘non-stem like’’) cell phenotype to
see how tumors that had been fully
established can exhaust over time.
Notably, when we performed conven-
tional xenotransplantation with ‘‘spon-
taneous’’ JARID1B-positive versus
JAR1D1B-negative phenotypes, there
was no significant difference in tumor-
initiation capacity between both popu-
lations. Single melanoma cells of either
population were equally tumorigenic.
As JARID1B-negative cells also gave
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rise to JAR1D1B-positive cells in vitro
and in vivo, we assume that stemness
in melanoma does not follow a static
but rather a dynamic model. Likely, a
select number of genes keeps melanoma
cells in a long-living status for contin-
uous repopulation of the tumor. The
Settleman laboratory recently pointed to
a new direction of clinical importance:
JARID1A, a close homolog of JARID1B,
is required for drug resistance in non-
small-cell lung cancer cells (Sharma
et al., 2010), which suggests that slow-
cycling cells survive most conventional
and targeted therapies and that this sub-
population requires specific targeting.
CONCLUSIONS: MICROENVIRON-
MENTAL CUES SWITCH ‘‘STEMNESS’’
Collectively, many recent studies on
melanoma stem cells suggest that intra-
tumoral heterogeneity exists but the
phenotypes are dynamic, not static.
Tumor maintaining sub-populations
likely continually arise and disappear.
The big question is how this switching
is controlled. Interestingly, conven-
tional melanoma culture conditions
allow a higher dynamic of the JARID1B
phenotype compared with human em-
bryonic stem cell culture conditions
(Roesch et al., 2010), suggesting solu-
ble factors as possible contributors to
the regulation of this equilibrium.
Additionally, hypoxia is a significant
stimulator for the expression of JAR-
ID1B (Xia et al., 2009; Roesch et al.,
2010). Overall, the tumor microenvir-
onment has a major role for the turn-
over and fate of CSC. In agreement with
this view, Hoek and Goding (2010)
recently framed the ‘‘phenotype-
switching model’’ of melanoma on
the basis of gene expression profiling
and functional analyses. In this model,
melanomas contain microphthalmia-
associated transcription factor-high,
Brn-2 (POU domain, class 3, transcrip-
tion factor 2)-low ‘‘proliferative’’ and
microphthalmia-associated transcription
factor-low, Brn-2 (POU domain, class 3,
transcription factor 2)-high ‘‘invasive,
stem-like’’ sub-populations. These phe-
notypes are distinct only temporarily
and each sub-population has the po-
tential to adopt the other phenotype in
response to exogenouse growth factors
such as transforming growth factor-b.
Stromal cell-secreted factors, such as
hepatocyte growth factor, can restore
the colon CSC phenotype in more
differentiated tumor cells (Vermeulen
et al., 2010), suggesting that the phe-
notypes of sub-populations can fluctu-
ate depending on the signals from the
tumor microenvironment. Therefore,
the development of effective therapies
against melanoma stemness remains a
major challenge. Targeting CSC and
responsible pathways may lead to an
abrogation of melanoma stemness. In
the future, we expect that the field will
develop therapies that target the ma-
jority of malignant cells, using, e.g., the
BRAF inhibitor PLX4032, as well as the
minor sub-population(s). Most likely,
the small non-proliferating or very
slowly proliferating JARID1B-positive
sub-population is a prime target for
developing therapies, to our knowl-
edge, previously unreported, that act in
synergy with those targeting the major
population of cells.
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